Uptake of medicines for type 2 diabetes

Empagliflozin (with and without metformin) has been funded since 1 February 2021 and dulaglutide has been funded since 1 September 2021. They are funded for people with high-risk type 2 diabetes who meet certain criteria.

A Pharmac first 

This was the first time we specifically name Māori and Pacific ethnicities within the funding criteria.  This was to proactively promote equity of access to this medicine. 

As part of the decision to fund this medicine, we said we would actively monitor and report on uptake. 

We update this information monthly. 

Empagliflozin (with & without metformin) and dulaglutide

Total number of people who have a Special Authority approved as at 7 November 2021: 43,929

Special Authority criteria

% of applications per criteria

Māori or Pacific ethnicity

47%

Pre-existing cardiovascular disease

23% 

5-year cardiovascular disease risk

29% 

High lifetime cardiovascular risk (childhood or young adult)

9% 

Diabetic kidney disease

18% 

Notes

Sum of percentage of each criteria will be greater than 100% as applicants may have ticked more than one criteria. 

The criteria for Māori or Pacific ethnicity is prioritised. If an applicant has ticked the Māori or Pacific ethnicity criteria, they do not need to tick another criteria. This means that the total number of applications will underrepresent those with cardiovascular and renal risk criteria.

People with a previous Special Authority approval for empagliflozin may have changed to dulaglutide, with a different Special Authority approval. This means that there may be some double-counting of approval numbers and the true number of individual people with an approval for one of the diabetes medicines may be slightly lower than the total numbers shared above.